NASDAQ:INDP

Indaptus Therapeutics Stock Insider Trading

etoro logo Buy INDP
*Your capital is at risk
$3.78
-0.125 (-3.21%)
At Close: Jun 22, 2026

Indaptus Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.81. In total, the insiders bought 114.31M and sold 913.49K INDP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
99.81
Buy 114.31M shares
Sell 913.49K shares
95% Buy Activity
Negligible or No Correlation
Sell Signal Low Confidence
Mar 23, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 99.81.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Apr 08, 2026
Buy
Common Stock
J-Other
Lu Qinglai
Director 0
Value: $0
Mar 23, 2026
Buy
Common Stock
Dai Junyi
Chief Executive Officer
CEO / President 0
Value: $0
Mar 23, 2026
Buy
Common Stock
Sino Lion Ventures Ltd
10 Percent Owner
10% Owner 0
Value: $0
Mar 23, 2026
Buy
Common Stock
Yao Yun
10 Percent Owner
10% Owner 0
Value: $0
Mar 23, 2026
Sell
Series AAA Convertible Non-Redeemable Preferred Stock
S-Sale
Lazar David E.
Director
Director 700 000
Value: $0
Mar 23, 2026
Sell
Series AA Convertible Non-Redeemable Preferred Stock
S-Sale
Lazar David E.
Director
Director 196 800
Value: $0
Feb 26, 2026
Buy
Common Stock
J-Other
Jabbour Jerome D
Director 0
Value: $0
Feb 26, 2026
Buy
Option to Buy Common Stock
A-Award
Jabbour Jerome D
Director
Director 25 000
Value: $51.5K
Feb 26, 2026
Buy
Common Stock
Mcmurdo Matthew Charles
Director
Director 0
Value: $0
Feb 11, 2026
Sell
Warrants (right to buy)
D-Return
Meckler Jeffrey A
Co-chief Executive Officer
CEO / President 1 519
Value: $44.7K
Feb 11, 2026
Sell
Warrants (right to buy)
D-Return
Meckler Jeffrey A
Co-chief Executive Officer
CEO / President 12 136
Value: $100.7K
Feb 11, 2026
Sell
Warrants (right to buy)
D-Return
Meckler Jeffrey A
Co-chief Executive Officer
CEO / President 3 033
Value: $144.4K
Feb 11, 2026
Buy
Warrants (right to buy)
A-Award
Meckler Jeffrey A
Co-chief Executive Officer
CEO / President 1 519
Value: $3K
Feb 11, 2026
Buy
Warrants (right to buy)
A-Award
Meckler Jeffrey A
Co-chief Executive Officer
CEO / President 3 033
Value: $5K
Feb 11, 2026
Buy
Warrants (right to buy)
A-Award
Meckler Jeffrey A
Co-chief Executive Officer
CEO / President 12 136
Value: $21.2K
Jan 20, 2026
Buy
Common Stock
A-Award
Ben-tzvi Avraham
Director
Director 25 000
Value: $72.3K
Jan 08, 2026
Buy
No securities are beneficially owned.
Natan David
Director
Director 0
Value: $0
Jan 07, 2026
Buy
Option to Buy Common Stock
A-Award
Natan David
Director
Director 25 000
Value: $67.3K
Dec 23, 2025
Buy
Option to Buy Common Stock
A-Award
Ben-tzvi Avraham
Director
Director 25 000
Value: $48.8K
Dec 22, 2025
Buy
Common Stock
A-Award
Linscott Walt Addison
Chief Operating Officer
C-Suite Officer 54 421
Value: $110.5K
Dec 22, 2025
Buy
Common Stock
A-Award
Newman Michael James
Cso And Director
Officer 52 204
Value: $106.0K
Dec 22, 2025
Buy
Common Stock
A-Award
Meckler Jeffrey A
Co-chief Executive Officer
CEO / President 216 617
Value: $439.7K
Dec 22, 2025
Buy
Common Stock
A-Award
Sassi Nir
Chief Financial Officer
C-Suite Officer 26 758
Value: $54.3K
Dec 22, 2025
Buy
Common Stock
Ben-tzvi Avraham
Director
Director 0
Value: $0
Dec 22, 2025
Buy
Common Stock
Lazar David E.
Co-chief Executive Officer
CEO / President 0
Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT INDAPTUS THERAPEUTICS, INC.
Indaptus Therapeutics
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was fo...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.29% Jun 10
PHM
$118.49
6.02% Jun 10
EAT
$140.46
17.09% Jun 05
E
ETD
$20.67
3.19% Jun 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE